Should I Buy URGN? URGN 2026 Analysis

Should You Buy Urogen Pharma Ltd (URGN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

20.690

1 Day change

-2.95%

52 Week Range

30.000

Analysis Updated At

2026/01/26

Urogen Pharma Ltd (URGN) is not a strong buy at the moment for a beginner investor with a long-term strategy. While hedge funds are increasing their positions, insider selling is significantly high, which raises concerns. Technical indicators are neutral, and there are no strong positive catalysts or trading signals to suggest immediate action. The company's financial performance shows improvement in revenue and net income, but it remains unprofitable. Given the lack of strong buy signals and the mixed sentiment, holding off on investing right now is the best course of action.

Technical Analysis

The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 46.339, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 20.679, with key resistance at 22.963 and support at 18.395.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Hedge funds are buying, with a 194.83% increase in buying activity over the last quarter. Revenue and net income have shown YoY improvements, with net income improving by 40.87%.

Neutral/Negative Catalysts

Insiders are selling heavily, with a 573.47% increase in selling activity over the last month. Gross margin has dropped by 2.44% YoY. No recent news or significant event-driven catalysts.

Financial Performance

In Q3 2025, revenue increased by 9.04% YoY to $27,482,000. Net income improved by 40.87% YoY but remains negative at -$33,347,000. EPS improved by 25.45% YoY to -0.69. Gross margin declined by 2.44% YoY to 88.07%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data on recent analyst ratings or price target changes.

4 Analyst Rating

Wall Street analysts forecast URGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for URGN is 40.25 USD with a low forecast of 31 USD and a high forecast of 55 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 21.320

Low

Averages

40.25

High

Current: 21.320

Low

Averages

40.25

High

Piper Sandler

Overweight

initiated

$36

AI Analysis

2025-08-19

Reason

Piper Sandler

Price Target

$36

AI Analysis

2025-08-19

initiated

Overweight

Reason

As previously reported, Piper Sandler initiated coverage of UroGen Pharma with an Overweight rating and $36 price target. Investors are starting to gain more confidence in the Zusduri launch, but the firm thinks the Street still underestimates peak sales potential in LG-IR-NMIBC and overestimates intellectual property risk to the -102/-103 franchise, the analyst contends. The firm sees early commercial launch datapoints, combined with updates from the Phase 3 UTOPIA trial of UGN-103, driving \"meaningful upside\" over the next 12-18 months.

Piper Sandler

NULL -> Overweight

initiated

$36

2025-08-18

Reason

Piper Sandler

Price Target

$36

2025-08-18

initiated

NULL -> Overweight

Reason

Piper Sandler initiated coverage of UroGen Pharma with an Overweight rating and $36 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for URGN

Unlock Now

URGN Should I Buy

URGN Should I Buy

Should You Buy Urogen Pharma Ltd (URGN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch